The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $11.26

Today's change+0.15 +1.35%
Updated September 4 4:15 PM EDT. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $11.26

Today's change+0.15 +1.35%
Updated September 4 4:15 PM EDT. Delayed by at least 15 minutes.

Nektar Therapeutics up (U.S.)$0.15

Nektar Therapeutics closed up Friday by (U.S.)$0.15 or 1.35% to (U.S.)$11.26. Over the last five days, shares have gained 3.59%, but are down 27.35% for the last year to date. Shares have underperformed the S&P 500 by 14.16% during the last year.

Key company metrics

  • Open(U.S.) $10.94
  • Previous close(U.S.) $11.11
  • High(U.S.) $11.48
  • Low(U.S.) $10.88
  • Bid / Ask(U.S.) $9.75 / (U.S.) $12.08
  • YTD % change-27.35%
  • Volume636,847
  • Average volume (10-day)1,455,675
  • Average volume (1-month)1,395,228
  • Average volume (3-month)1,689,045
  • 52-week range(U.S.) $9.16 to (U.S.) $17.53
  • Beta1.57
  • Trailing P/E371.37×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.03
Updated September 4 4:15 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2.14%

Based on its net profit margin of 2.14%, Nektar Therapeutics is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.87%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue2310920133
Total other revenue--------
Total revenue2310920133
Gross profit1210013124
Total cost of revenue11869
Total operating expense66665753
Selling / general / administrative1010129
Research & development45473834
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----0--
Other operating expenses, total--------
Operating income-4343-3780
Interest income (expense), net non-operating-9-9-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-5234-4771
Income after tax-5334-4671
Income tax, total00-10
Net income-5334-4671
Total adjustments to net income--------
Net income before extra. items-5334-4671
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-5334-4671
Inc. avail. to common incl. extra. items-5334-4671
Diluted net income-5334-4671
Dilution adjustment--------
Diluted weighted average shares132136129132
Diluted EPS excluding extraordinary itemsvalue per share-0.400.25-0.350.53
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.400.25-0.350.53